Lista de obras - Mhairi Copland - Dominio Público Uruguay

A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells

artículo científico publicado en 2014

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

artículo científico publicado en 2020

Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience

scientific article published on 03 July 2013

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation

artículo científico publicado en 2013

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

artículo científico publicado en 2006

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.

artículo científico publicado en 2009

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

artículo científico publicado en 2007

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

artículo científico publicado en 2020

Cancer stem cell definitions and terminology: the devil is in the details.

artículo científico publicado en 2012

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

artículo científico publicado en 2011

Chronic myelogenous leukemia stem cells: What's new?

artículo científico publicado en 2009

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation

artículo científico publicado en 2012

Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia

artículo científico publicado en 2008

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

scientific article published on 31 January 2020

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

artículo científico publicado en 2014

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

artículo científico publicado en 2006

EZH2 in normal and malignant hematopoiesis

artículo científico publicado en 2013

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

scientific article published on December 2008

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

artículo científico publicado en 2012

Evolving molecular therapy for chronic myeloid leukaemia--are we on target?

artículo científico publicado en 2005

Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).

artículo científico publicado en 2002

Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

artículo científico publicado en 2005

Hedgehog signaling in cancer stem cells: a focus on hematological cancers.

artículo científico publicado en 2015

Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.

artículo científico publicado en 2013

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia

artículo científico publicado en 2016

How I manage priapism in chronic myeloid leukaemia patients.

artículo científico publicado en 2012

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach

artículo científico publicado en 2007

In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors

artículo científico publicado en 2014

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

artículo científico publicado en 2006

Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform

artículo científico publicado en 2012

Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells

artículo científico publicado en 2009

Novel drug therapies in myeloid leukemia

artículo científico

Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation

artículo científico publicado en 2001

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

artículo científico publicado en 2013

Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection

artículo científico publicado en 2005

Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.

artículo científico publicado en 2013

Targeting chronic myeloid leukemia stem cells.

artículo científico

Targeting hedgehog in hematologic malignancy.

artículo científico

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

artículo científico publicado en 2004

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells ⬇️

artículo científico publicado en 2011

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors

artículo científico publicado en 2014

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML

scientific article published on 06 January 2020

The role of the bone morphogenetic proteins in leukaemic stem cell persistence.

artículo científico publicado en 2014

The use of a risk group stratification in the management of invasive fungal infection: a prospective validation

artículo científico publicado en 2004

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

artículo científico publicado en 2022

Lista de obras de Mhairi Copland

A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Cancer stem cell definitions and terminology: the devil is in the details.

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Chronic myelogenous leukemia stem cells: What's new?

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation

Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

EZH2 in normal and malignant hematopoiesis

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia.

Evolving molecular therapy for chronic myeloid leukaemia--are we on target?

Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).

Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia

Hedgehog signaling in cancer stem cells: a focus on hematological cancers.

Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications.

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia

How I manage priapism in chronic myeloid leukaemia patients.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach

In a 12-allele analysis HLA-DPB1 matching is associated with improved OS in leukaemic and myelodysplastic patients receiving myeloablative T-cell-depleted PBSCT from unrelated donors

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate

Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform

Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells

Novel drug therapies in myeloid leukemia

Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile

Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection

Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients.

Targeting chronic myeloid leukemia stem cells.

Targeting hedgehog in hematologic malignancy.

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells ⬇️

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors

The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML

The role of the bone morphogenetic proteins in leukaemic stem cell persistence.

The use of a risk group stratification in the management of invasive fungal infection: a prospective validation

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy

Tyrosine kinase inhibitor independent gene expression signature in CML offers new targets for LSPC eradication therapy